Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $2.47M invested in Proshares UltraPro NASDAQ Biotechnology in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
8,314% more call options, than puts
Call options by funds: $589K | Put options by funds: $7K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less capital invested
Capital invested by funds: $4.37M → $2.47M (-$1.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$1.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$260K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$149K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$5.52K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$322K |
| 2 |
Jane Street
New York
|
-$310K |
| 3 |
CT
CMT Trading
Chicago,
Illinois
|
-$250K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$53.5K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$18.5K |
UBIO Hedge Fund Activity: Q1 2016 in Review
7 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q1 2016, worth a combined $2.47M — down 43% from $4.37M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of UBIO and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, adding an estimated $1.03M. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $322K sold.
- 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q1 2016, down from 8 in Q4 2015.
- Funds reported $2.47M of Proshares UltraPro NASDAQ Biotechnology stock for Q1 2016, down 43% quarter-over-quarter.
- 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q1 2016 and 3 closed out, a net change of -1 holder.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q1 2016 was Virtu Financial, an estimated $1.03M added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q1 2016 was Virtu KCG Holdings, an estimated $322K sold.
Based on aggregated 13F filings for Q1 2016.